Maixin Biotech

Fuzhou Maixin Biotech,Ltd. was established in 1993, with a registered capital of 50 million yuan, located in the High-tech Industrial Park of Haixi, Fuzhou High-tech Zone, Fujian Province. It is a leading company in China's tumor pathology immunohistochemistry diagnostic reagents and a high-tech enterprise in the biopharmaceuticals industry. Its businesses cover multiple fields such as tumor pathology diagnosis, immunocytochemistry diagnosis, molecular pathology diagnosis, and precision medicine diagnosis, with a marketing network spread across the country. Maixin was the first domestic company to obtain the NMPA (formerly CFDA) Class III medical device production license for immunohistochemistry products and currently owns 52 patents. In 2013, Maixin officially moved into the Innovation Park of Haixi Industrial Park in Fuzhou High-tech Zone, vigorously promoting the development of key technologies and products to improve the localization level of tumor diagnostic reagents and equipment. In the same year, the company launched its self-developed monoclonal antibodies with the "MX" clone label, which now exceed one hundred varieties. In 2015, the first domestically developed fully automatic immunohistochemical staining system (Titan) was successfully launched. In 2016, newly developed molecular pathology diagnostic products, RedBright TM FISH probes, with excellent performance were released.As early as 1999, Maixin established the first immunohistochemistry quality control laboratory in China. In 2016, Maixin successfully passed the ISO9001 and ISO13485 audits and certifications. In 2017, the "Maixin Pathology Diagnosis Center" obtained a medical institution practice license and became a key project under the Fujian Provincial Government’s "Five Batches" initiative. Meanwhile, Maixin participated as a drafting unit in formulating the industry standard for "Immunohistochemistry Reagent Kits" and contributed to the writing of several domestic pathological academic monographs. The company has always actively participated in industry association/pathology society activities and undertaken multiple important tasks. Becoming an innovative enterprise with social responsibility and industry responsibility has always been Maixin’s direction of progress.